Jon Persichino, DO
Infectious Disease · Riverside, CANPI 1619905189
Payments from drug & device makers
Across 173 payments — averaging $1364.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$217K
- Karyopharm Therapeutics Inc.$11K
- Gilead$4K
- Viiv Healthcare Company$1K
- Shionogi Inc$698
- AbbVie$571
- plus $2K from 18 others
What the payments were for
- Consulting fees$3,26040%
- Travel & lodging$661%
- Food & beverage$4,22952%
- Education$5887%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $217,202 |
| Karyopharm Therapeutics Inc. | 2 | $10,700 |
| Gilead | 15 | $3,725 |
| Viiv Healthcare Company | 55 | $1,384 |
| Shionogi Inc | 12 | $698 |
| AbbVie(2 entities) | 32 | $571 |
| Melinta Therapeutics, LLC | 4 | $257 |
| Insmed, Inc. | 2 | $169 |
| Janssen Products, LP | 2 | $164 |
| Johnson & Johnson(2 entities) | 12 | $155 |
| Merck | 5 | $149 |
| Paratek Pharmaceuticals, Inc. | 5 | $134 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
| Astellas Pharma US Inc | 4 | $113 |
| Boehringer Ingelheim | 3 | $89 |
| GSK | 4 | $86 |
| Lilly USA, LLC | 2 | $51 |
| Novo Nordisk | 2 | $44 |
| EMD Serono, Inc. | 1 | $27 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Theratechnologies Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$236,045 in reported general payments places this provider in the 90th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 264 | $1,106,488 |
| JulucaDolutegravir/Rilpivirine | 122 | $454,098 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 62 | $325,827 |
| DovatoDolutegravir Sodium/Lamivudine | 70 | $237,608 |
| TivicayDolutegravir Sodium | 95 | $227,932 |
| DescovyEmtricitabine/Tenofov Alafenam | 83 | $199,192 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 29 | $154,461 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 29 | $107,442 |
| CabenuvaCabotegravir/Rilpivirine | 12 | $88,222 |
| PrezcobixDarunavir/Cobicistat | 34 | $78,651 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 19 | $64,904 |
| Efavirenz-Lamivu-Tenofov DisopEfavirenz/Lamivu/Tenofov Disop | 11 | $14,934 |
| Fluconazole | 92 | $5,819 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,031 |
| Methenamine Hippurate | 42 | $2,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $3,725 | $1,460,141376 claims |
| Viiv Healthcare CompanyJuluca, Dovato, Tivicay, Triumeq, Cabenuva | $1,384 | $1,115,302328 claims |
| Janssen Products, LPSymtuza | $164 | $325,82762 claims |
| Johnson & JohnsonPrezcobix | $155 | $78,65134 claims |
| GSKIncruse Ellipta | $86 | $4,03112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 856 infectious disease providers in California.
Other infectious disease in Riverside
- Peter RuaneLos Angeles$24.6M
- Raphael LandovitzLos Angeles$21.4M
- Philip RobinsonNewport Beach$4.9M
- Shawn HasslerSan Francisco$4.3M
- James McKinnellTorrance$4.3M
- Loren MillerTorrance$4.1M
- Jay GladsteinLos Angeles$4M
- Claire PomeroySacramento$3.8M
- Franco FelizartaBakersfield$3.5M
- Abhijit LimayeSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.